SIRDALUD tablett Eesti - eesti - Ravimiamet

sirdalud tablett

sandoz pharmaceuticals d.d. - tisanidiin - tablett - 2mg 30tk

SIRDALUD tablett Eesti - eesti - Ravimiamet

sirdalud tablett

sandoz pharmaceuticals d.d. - tisanidiin - tablett - 4mg 30tk

SIRDALUD tablett Eesti - eesti - Ravimiamet

sirdalud tablett

lex ano uab - tisanidiin - tablett - 2mg 30tk

SIRDALUD tablett Eesti - eesti - Ravimiamet

sirdalud tablett

ideal trade links uab - tisanidiin - tablett - 4mg 30tk

SIRDALUD tablett Eesti - eesti - Ravimiamet

sirdalud tablett

ideal trade links uab - tisanidiin - tablett - 2mg 100tk; 2mg 30tk

SIRDALUD tablett Eesti - eesti - Ravimiamet

sirdalud tablett

ideal trade links uab - tisanidiin - tablett - 4mg 30tk; 4mg 100tk

SIRDALUD tablett Eesti - eesti - Ravimiamet

sirdalud tablett

ideal trade links uab - tisanidiin - tablett - 2mg 30tk; 2mg 100tk

Namuscla Euroopa Liit - eesti - EMA (European Medicines Agency)

namuscla

lupin europe gmbh - mexiletine hydrochloride - myotonic häired - südame teraapia - namuscla on näidustatud sümptomaatiline ravi myotonia täiskasvanud patsientidel, kellel on mitte-huumustoiteline myotonic häired.

Tabrecta Euroopa Liit - eesti - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Fintepla Euroopa Liit - eesti - EMA (European Medicines Agency)

fintepla

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptics, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.